Publications

5898 Results

Lung-MAP S1800E: A randomized phase II/III study of docetaxel and ramucirumab with or without cemiplimab for patients previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)

Authors
S Waqar;Redman MW;Li T;Minichiello K;Dragnev KH;Borghaei H;Bradley JD;Brahmer JR;Stinchcombe T;Gray JE;Herbst RS;Reckamp KL;Gandara DR
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); TIP TPS8669 poster
Year
2026
Research Committee(s)
Lung
Study Number(s)
S1800E

Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer

Authors
Sinicrope FA;Ou FS;Arnold D;Peters WR;Behrens RJ;Lieu CH;Matin K;Cohen DJ;Potter SL;Nixon AB;Kottschade LA;Kathol E;Frankel WL;Shergill A;Hsu D;Reinacher-Schick A;Mehan P;Gold PJ;Khalil MF;Zemla T;Gatten C;O‘Reilly EM;Meyerhardt JA
Journal / Conference
New England Journal of Medicine. 2026 Mar 25; 394: 1155-1166. DOI: 10.1056/NEJMoa2507874.
Year
2026
Research Committee(s)
Gastrointestinal
PMID
41880612
PMC
PMC13020640
Study Number(s)
CTSU/A021502

Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602)

Authors
Strosberg JR;Zemla T;Geyer S;Pulsipher S;Ou FS;Behr S;Raj N;Vijayvergia N;Dasari A;O‘Reilly EM;Meyerhardt JA;Wolin EM;Halfdanarson TR;Chan JA
Journal / Conference
Endocrine-Related Cancer. 2026 Jan 24; 33: e250415. DOI: 10.1530/ERC-25-0415. Print 2026 Jan 1
Year
2026
Research Committee(s)
Gastrointestinal
PMID
PMID41524552
Study Number(s)
CTSU/A021602

PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials

Authors
Booth A;Hillman S;Laumann K;Zhao YQ;LeBlanc M;Chansky K;Giri S;Dill J;Johnson J;Kelley K;Martin L;Osarogiagbon RU;Morris MJ;Chiang AC;Kozono DE;Blanke CD;Galanis E;Gray JE;Stinchcombe TE;Aljumaily R;Morgensztern D;Mandrekar SJ
Journal / Conference
Journal of Thoracic Oncology. 2026 Feb 24; 103650. DOI: 10.1016/j.jtho.2026.103650.
Year
2026
Research Committee(s)
Lung
PMID
PMID41747891
PMC
PMC13095140

Composition of Health Care Contact Days and Mortality Prediction Among Older Adult Clinical Trial Participants

Authors
Gupta A;Till C;LeBlanc ML;Hershman DL;Unger JM
Journal / Conference
JCO Oncology Practice. 2026 Apr 1; OP-25-01182. DOI: 10.1200/OP-25-01182.
Year
2026
Research Committee(s)
Cancer Care Delivery
PMID
41921118

Reassessing Treatment Outcomes Following Immune-Related Adverse Events-Reply

Authors
Unger JM;Hershman DL
Journal / Conference
JAMA Oncology. 2026 Apr 23; . DOI: 10.1001/jamaoncol.2026.0785. Letter (reply RE 10.1001/jamaoncol.2025.5549 [PubID 6714])
Year
2026

Incorporating Intensity Modulated Total Body Irradiation (IMRT-TBI) Into Future Cooperative Group Clinical Trials: An NRG Hematologic Malignancies Working Group-Led Report From the National Clinical Trials Network

Authors
Kovalchuk N;Simiele EA;LaRiviere M;Hiniker SM;Soike M;Han C;Wong J;Dandapani S;Kumar K;Parsons D;Teruel JR;Gerber NK;Guo B;Cherian S;Lim TY;Latifi K;Figura NB;Shrestha DK;Grecula J;Sim AJ;Parikh RR;Lo AC;Smith K;Plastaras JP;Xiao Y;Hoppe BS;Milgrom SA
Journal / Conference
International Journal of Radiation Oncology, Biology, Physics. 2026 Feb 17; S0360-3016(26)00388-3. DOI: 10.1016/j.ijrobp.2026.02.201. Online ahead of print
Year
2026
PMID
PMID41713515

Integrating Oncology APPs and Clinical Pharmacists into Clinical Cancer Research

Authors
Braun-Inglis C;Myers J;O‘Brien B;Kottschade L;Flannery M;Detroye AT;Elko T;Leatherwood A;Mader A;Wong SF;Foust M;Bakitas M;Benson AB;Berenberg JL;Primeaux B;Rosenzweig M;Demirhan K;Statler T;Vogel W
Journal / Conference
Journal of the National Cancer Institute. 2026 Apr 21; djag125. DOI: 10.1093/jnci/djag125.
Year
2026

Cancer statistics, 2026: Charting a course for a national cancer research agenda

Authors
Lara PN;Hershman DL
Journal / Conference
CA: A Cancer Journal for Clinicians. 2026 Jan 13; 76: e70061. DOI: 10.3322/caac.70061. editorial
Year
2026
Research Committee(s)
Multiple sites

Consensus radiation therapy organ at risk constraints for NCTN trials in hematologic malignancies

Authors
Sim AJ;Hoppe BS;Ballas LK;Milgrom SA;Terezakis SA;Ha CS;Figura NB;Parikh RR;Grecula JC;Plastaras JP;Lo AC;Ryckman J;Flampouri S;Pinnix CC;Kelsey CR
Journal / Conference
Journal of the National Cancer Institute. 2026 Apr 7; djag112. DOI: 10.1093/jnci/djag112.
Year
2026
PMID
13249543
PMC
PMC41965109